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Background: The incidence of  tuberculosis among HIV-infected populations with high CD4 count in high burden countries 
has not been well studied.
Objective: To assess the TB incidence in HIV-infected adults and its associated risk factors.
Method: A cohort study with retrospective review of  medical records and prospective follow-up of  HIV-infected adult partici-
pants attending CTC who were 18-55 years old, had CD4 count more than 250 cells/mm3 in the period of  2008-2010 and were 
not on ART at enrolment. Cox proportional hazard regression was used to explore the predictors of  incident TB.
Results: Overall 777 (24%) of  3,279 CTC enrolled HIV-infected adults fulfilled the inclusion criteria of  the study. The incidence 
of  TB in the study population ranged from 0.8/100 per person years (PY) at risk (95% CI 0.5-1.3) in the main analysis to 1.7/100 
PY at risk (95% CI 1.0-2.6) in sensitivity analyses. Only prior history of  TB disease was found to have a significant association 
with an increased risk of  TB, hazard ratio 5.7 (95% CI 2.0-16.4, p value 0.001).
Conclusion: Tuberculosis incidence among HIV-infected adults with medium/high CD4 count in Bagamoyo is lower than in 
other high TB burden countries. Previously TB treated patients have a much higher risk of  getting TB again than those who 
never had TB before.
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Previous studies on HIV and Tuberculosis co-infection 
reported varying TB incidences among HIV-infected 
population in high burden countries. A systematic review 
was done on TB incidence among HIV infected persons 
on ART1, but only very few studies have been done on TB 
incidence among ART naïve HIV-infected persons with 
medium/high CD4 count not on ART2–4. The lowest and 
highest incidences in these studies were 2.7 and 10.5 per 
100 person years (PY), respectively, both reported from 
South Africa3,4. We chose to study this group since for a 
vaccine trial it was considered to include persons not on 
ART at the time of  the study; and since HIV infected 
persons with medium/high CD4 count were often not 
on ART, although current recommendations are to give 
ART in persons living with HIV at any CD4 cell count5.
In its End TB strategy, the World Health Organization 
(WHO) emphasizes treatment coverage to be 90% or 
more of  total estimated TB cases annually6. This may be 
achieved when high-risk populations such as HIV-infect-
ed individuals are systematically screened and timely di-
agnosed. The study was designed to assess suitability of  
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this population for vaccine trials and to determine TB 
screening strategies for HIV infected ART naïve persons. 
The specific objectives of  this study were to measure the 
incidence of  TB and its associated risk factors. This type 
of  studies is rarely done and this information is useful to 
determine TB screening strategies for HIV-infected per-
sons. We chose a rural area, since other studies have often 




The study was conducted in Bagamoyo District approxi-
mately 65 kilometers north of  Dar es Salaam. The district 
has an estimated population of  311,740 (7). Data collec-
tion was done between June 2011 and June 2012. The two 
largest CTCs (Bagamoyo District Hospital and Chalinze 
Health Center) were selected for this study among seven 
CTCs which all offer HIV/TB collaboration activities. 
The study population comprised of  patients enrolled to 
receive HIV care and treatment in two CTCs between 
2008 and 2010.
Study design
We enrolled adults aged 18-55 years old from a cohort of  
HIV-infected individuals in the Bagamoyo District who 
had CD4 count more than 250 cells/mm3, had person-
al identifiers, locator information and were not on ART 
at enrolment to determine the incidence of  TB and its 
predictors. Pre-ART registers of  the National AIDS 
Control Program from 2008 to 2010 were reviewed to 
collect: unique CTC identification numbers, age and base-
line CD4 cell count. Participants who were put on ART 
during CTC recruitment visit were excluded. Those who 
met the inclusion criteria were recruited and had their 
medical record reviewed to collect information on gen-
der, TB status until 30 June 2012, baseline WHO clinical 
stage and ART status at follow-up. Recruited participants 
were interviewed using a structured questionnaire during 
their respective CTC follow-up visits or at home. A home 
visit to conduct interviews was done once. Participants 
that were not seen during their respective scheduled fol-
low-up or home visits were considered lost to follow-up. 
For all TB cases, we reviewed TB Treatment and Labora-
tory registers to collect information on TB diagnosis date, 
smear results, type of  TB, treatment start and end dates. 
A participant was considered a TB case if: smear-posi-
tive results were documented in the laboratory register 
and/or medical folder or the patient had smear-negative 
or missing smear results but had clinical signs and symp-
toms highly suggestive of  TB, as determined by the treat-
ing clinician.
Definitions
Participants were classified into three categories accord-
ing to the CD4+-T-cell counts at enrollment: high (>500 
cells/μl), medium (200 to 500 cells/μl) and low (<200 
cells/μl).
Prevalent TB cases was defined as TB cases on treatment 
at enrolment or diagnosed within 3 months after enrol-
ment.
Incident TB case was defined as TB case on treatment 
diagnosed more than 3 months after CTC enrolment.
Statistical analysis
Data was analyzed using STATA version 13 (College 
Station, Texas, USA). Differences in proportions were 
compared using χ² test. A p-value of  0.05 was considered 
significant. Person-time at risk for TB was accrued from 
the date participant was enrolled into CTC until date of  
death, TB diagnosis or end of  follow-up or end of  ob-
servations on 30 June 2012, whichever occurred first (for 
the main analysis). TB cases on treatment at enrolment or 
diagnosed within 3 months after enrolment were consid-
ered prevalent cases.
Risk factors for incident TB were analysed by Cox pro-
portional hazard ratio (HR). Risk factor analysis for TB 
included age, gender, WHO clinical stage, CD4 cell count 
at enrollment (250-350 and >350 cells/mm3), previous 
history of  TB documented and ART start during fol-
low-up were considered based on clinical relevance and 
availability.
Main analysis: 
Date participant enrolled into CTC was considered as 
start date except for prevalent TB cases whose start date 
was a year after TB treatment completion. We assumed 
all participants were still living in the area, and all not reg-
istered in the TB register were assumed not to have TB 
until 30 June 2012.
In the sensitivity analysis we analyzed the effect of  the 
assumption in the main analysis and varied assumptions 
on the point estimate and on the risk factors.
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Sensitivity analysis I: As in main analysis, but we exclud-
ed 35 participants who were not seen after enrollment 
visit (2 of  these had TB at enrolment) since they may 
have moved outside the area, and their life status (alive or 
dead) and TB status (TB or no TB) was unknown to us.
Sensitivity analysis II: as in Sensitivity Analysis I and we 
considered the end of  follow-up to be date of  TB diag-
nosis, last visit date (instead of  30 June 2012) or date of  
death whichever occurred first.
Sensitivity analysis III: As in sensitivity analysis II, but 
in addition we excluded 32 prevalent cases since those 
patients were probably identified with HIV due to TB 
symptoms, and therefore may not be representative for all 
HIV-infected persons with the selected CD4 cell count.
Ethical consideration
The study was approved by Ifakara Health Institute-In-
stitutional Review Board (IHI/IRB/No.07-2011) and the 
Medical Research Coordinating Committee of  National 
Institute of  Medical Research (NIMR/HQ/R.8a/Vol.
IX/1137).
Permission to review Pre-ART registers was obtained 
from the District Medical Office and District HIV Co-
ordinator. All interviewed participants gave written in-
formed consent before the interview.
Results
General characteristics
Among 3279 patients’ pre ART records of  CTC reviewed 
from 2008 to 2010, 777 (24%)  met the inclusion crite-
ria and further review of  their medical folders was done 
(Figure 1). Reasons for exclusion of  2,502 (76%) patients 
shown in Figure 1.
23 with TB at 
enrolment;





9 with TB at 
enrolment;















Figure 1: Flow chart showing CTC participants between 2008 and 2010
2502 not eligible
Reasons: 
Age <18 or >55 years
CD4 cell count <250 cells/mm3
CTC enrollment earlier than 2008
Missing date of first CD4 cell count
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Of  the 777 participants, most were women 561/777 
(72%), 446/777 (57%) aged between 18 and 35 years; me-
dian age was 34 years (interquartile range, [IQR] 29-41). 
The median baseline CD4 cell count was 458 cells/mm3 
(IQR 349-616): 580/777 (75%) had CD4 cell count >350 
cells/mm3. A history of  TB was registered in 49 (6%) 
of  the participants. The prevalence of  TB at enrolment 
was 34/777 (4.4%); 142 patients (18%) were documented 
to have started ART during follow-up (Table 1). Among 
enrolled participants, those with follow-up visit (at home 
or in clinic) were comparable to those without follow-up 
visit, except that those with follow-up were more often 
females, had a lower WHO HIV clinical stage and more 
often started ART, although these differences were small 
(Table 1).
Table 1 Participants characteristic at baseline 
    Characteristics   Total participants 
N=777, n (%) 
With follow-up * 
N=350, n (%) 
Without follow-up* 
N=427, n (%) 
χ2 * P value* 
Sex Male 216 (28) 79 (23) 137 (32) 8.7 0.003 
  Female 561 (72) 271 (77) 290 (68)     
Age (years) 18-35 446 (57) 189 (54) 257 (60) 3.0 0.08 
  36-55 331 (43) 161(46) 170 (40)     
WHO stage 1 365 (47) 192 (55) 173 (41) 2.1 0.1 
  
 2                                              168 (21)              77 (22)                 91 (21)     
  3 161 (21)             60 (17)                 101 (24)                 10.5                  0.001 0.001 
  4                                               29 (4)        8 (2)              21 (5)           6.7                 0.009 0.009 
  Unclassified                             54 (7)           13 (4)             41 (10)                15.3                   <0.001  
Baseline CD4 
250-350 197 (25)             91 (26)             106 (25)        0.1 0.7 
  >350 580 (75) 259 (74)             321 (75)     
ART start during follow-up 
Yes 142 (18) 83 (24)             59 (14)     
  No 504 (65) 246 (70) 258 (60)        4.1 0.04 
  Undocumented 131 (17) 21 (6) 110 (26)       52.0 <0.001 
Previous TB history No episode 720 (93) 322 (97) 401 (94)     
  At least 1 
episode 
49 (6) 9 (2) 19 (4)        1.7 0.2 
  Unknown 8 (1) 0 (0) 7 (1.6)       5.6 0.02 
* Comparing those with follow-up visit with those without follow-up visit 
TB incidence rate
Main analysis
In this analysis, 18 of  777 participants were incident TB 
cases; 7 were smear-positive, 3 were smear-negative and 
8 TB cases smear results were not documented. Five par-
ticipants were on ART at the time of  TB diagnosis and 
13 were started on ART after being diagnosed with TB. 
The total survival time was 2197 PY. Overall TB inci-
dence rate was 0.8 per 100 PY at risk (95% CI 0.5-1.3). 
Only one available risk factor, having at least one previ-
ous TB episode, was significantly associated with a higher 
TB incidence (rate 3.5; 95% CI 1.4-8.4), (HR 5.7, 95% 
CI 2.0-16.4, p= 0.001) compared to those who report no 







χ2 * P value*
Sex Male 216 (28) 79 (23) 137 (32) 8.7 0.003
Female 561 (72) 271 (77) 290 (68)
Age (years) 18-35 446 (57) 189 (54) 257 (60) 3.0 0.08
36-55 331 (43) 161(46) 170 (40)
WHO stage 1 365 (47) 192 (55) 173 (41) 2.1 0.1
2 168 (21) 77 (22) 91 (21)
3 161 (21) 60 (17) 101 (24) 10.5 0.001
4 29 (4) 8 (2) 21 (5) 6.7 0.009
Unclassified 54 (7) 13 (4) 41 (10) 15.3 <0.001
Baseline CD4 250-350 197 (25) 91 (26) 6 (25) 0.1 0.7
>350 580 (75) 259 (74) 321 (75)
ART start during follow-up Yes 142 (18) 83 (24) 59 (14)
No 504 (65) 246 (70) 258 (60) 4.1 0.04
Undocumen
ted
131 (17) 21 (6) 110 (26) 52.0 <0.001
Previous TB history No episode 720 (93) 322 (97) 401 (94)
At least 1 
episode
49 (6) 9 (2) 19 (4) 1.7 0.2
Unknown 8 (1) 0 (0) 7 (1.6) 5.6 0.02
Table 1 Participants characteristic at baseline
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Female gender, age less than 36 years, baseline CD4 cell 
count >350 cells/mm3 and not being started on ART 
seemed to be associated with lower TB incidence rate, 
but were all not significant.
Sensitivity analyses
The TB incidences among HIV-infected population with 
CD4 count higher than 250 cells/mm3 were higher in 
all 3 sensitivity analyses compared to the main analysis 
(0.8 per 100 PY, 95% CI 0.5-1.3), being 0.9/100 PY (95% 
CI 0.5-1.4), 1.6/100 PY (95% CI 1.0-2.6), and 1.7/100 
PY (95% CI 1.0-2.6) in sensitivity analysis I, II and III, 
respectively (Table 3). A comparison of  risk factors be-
tween different sensitivity analyses showed that hazard 
ratios were similar; the same risk factor (previous TB) 
remained significant and no new significant risk factors 
were found (table 3).
Table 2: Cox regression analysis of risk factor for TB incidence
Risk factors Total enrollees
Included, 
N=777
Incident TB cases Total time at 
risk (years)






Sex Male 216 6 592 1.0 (0.4-2.3) 1 0.5
Female 561 12 1571 0.8 (0.4-1.3) 0.7 (0.3-1.9)
Age
(years)
18-35 446 8 1232 0.6 (0.3-1.3) 1 0.3
36-55 331 10 931 1.0 (0.6-2.0) 1.6 (0.6-4.1)
WHO
Stage
1 365 8 958 0.8 (0.4-1.7) 1 0.7
2 168 5 482 1.0 (0.4-2.5) 0.8 (0.3-2.4)
3 161 5 477 1.0 (0.4-2.5) 0.8 (0.2-2.4) 0.6
4 29 0 79 na na -
Unclassified 54 0 164 na na -
Baseline
CD4
250-350 197 6 554 1.1 (0.5-2.4) 1 0.7




No 578 11 1591 0.7 (0.4-1.2) 1 0.1
Yes 148 7 438 1.6 (0.7-3.4) 2.1 (0.8-5.4)
Not documented 51 0 133 0 na -
Previous
TB history
No episode 720 13 2009 0.6 (0.4-1.1) 1
1 or more episodes 49 5 128 3.9 (1.6-9.4) 6.2 (2.2-17.7) 0.001
Unknown 8 0 26 0 na -
Total 777 18 2163 0.8 (0.5-1.3)
CI: Confidence interval, Na: Not applicable
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Discussion
The study assessed TB incidence rates and its associated 
risk factors for HIV-infected adults with CD4 >250/mm3 
in rural Tanzania. The TB incidence was 0.8/100 PY at 
risk; and was higher (between 0.9 and 1.7/100 PY at risk) 
with different sensitivity analyses. This tendency is due 
to fewer persons and less follow-up time being included 
compared to the main analysis. Those who did not partic-
ipate in the follow-up are more likely to be alive and hav-
ing no TB, than being dead or having TB, assuming that, 
if  they suffered from TB or had HIV related co-mor-
bidities they would have attended CTCs. Therefore we 
consider the main analysis the most accurate one, though 
TB incidence might be slightly underestimated.
The overall TB incidence among HIV-infected adults was 
low, this may be explained by high CD4 count. TB in HIV 
infection depends on the person’s immune status (host), 
on the virulence of  the virus (agent) and on external fac-
tors such as reinfections8,9. The incidence is lower than 
that reported in a systematic review summarizing findings 
from 32 cohorts of  HIV-infected patients from high and 
intermediate tuberculosis burden settings taking ART1. A 
study in Ifakara, another rural area in Tanzania report-
ed the TB incidence among HIV-infected persons to be 
3.4/100 PY2. In that study patients had no prior history 
of  TB, had more often stage 3 or 4 disease (43% versus 
24% in our study), and lower CD4 cell count. The TB in-
cidence rate was also lower than that reported by a study 
in Dar es Salaam where the incidence among HIV-infect-
ed children <15 years was 5.2/100 PY at risk10. However, 
our study population was adults and had higher CD4 cell 
counts relative to that in Dar es Salaam. Furthermore, 
our study setting was Pwani Region where TB notifica-
tion rate was 187 per 100,000 population, lower than that 
of  Dar es Salaam (428 per 100,000 population in year 
2012)11
Our study found only one risk factor i.e. previous TB 
to be significantly associated with higher TB incidence. 
Other risk factors: gender, levels of  CD4 cell count and 














































Total 735 18 2083 0.9(0.5-
1.4)
717 18 1105 1.6(1.0-
2.6)
703 18 1087 1.7(1.0-2.6)
Sex M 205 6 581 1.0 (0.5-
2.3)
1 195 6 280 2.1 (1.0-
4.8)
1 186 6 268 2.2 (1.0-
5.0)
1













18-35 414 8 1162 0.7 (0.3-
1.4)
1 404 8 600 1.3 (0.7-
2.7)
1 398 8 594 1.3 (0.7-
2.7)
1













1 347 8 545 1.5 (0.7-
2.9)
1 347 8 545 1.5 (0.7-
3.0)
1 345 8 543 1.5 (0.7-
3.0)
1
2 160 5 257 1.9 (0.8-
4.7)
1.3 160 5 257 2.0 (0.8-
4.7)
1.3 159 5 256 2.0 (0.8-
4.7)
0.9(0.3-2.9)
3 144 5 226 2.2 (0.9-
5.3)
1.5 144 5 226 2.2 (1.0-
5.3)
1.5 133 5 211 2.4 (1.0-
5.7)
1.1(0.3-3.4)
4 24 0 32 0 (0-0) na 24 0 32 0 (0-0) na 24 0 32 0 (0-0) na






189 6 538 1.1 (0.5-
2.5)
1 187 6 285 2.1 (1.0-
4.7)
1 182 6 275 2.2 (1.0-
4.9)
1















No 547 11 1534 0.7 (0.4-
1.3)
1 531 11 787 1.3 (0.8-
2.5)
1 524 11 781 1.4 (0.8-
2.5)
1



















0 682 13 1927 0.7 (0.4-
1.2)
1 674 13 1049 1.2 (0.7-
2.1)
















31 5 45 11.1 (4.6-
26.6)
5.2(1.7-15.4)
# 7 0 23 0 (0-0) na 6 0 5 0 (0-0) na 6 0 5 0 (0-0) na
Table 3: Cox regression analysis of the risk factor for TB incidence 
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ART start during follow-up were possibly not significant 
due to low numbers of  patients included in analysis and 
therefore low power. The findings were consistent with 
those by Saha and Saha12 where the risk of  TB among 
patients with past history of  TB was 5 times higher than 
among those without previous TB. In the above study in 
Ifakara, WHO clinical stage 3 or 4 and being ART naïve 
were seen to be independent predictors of  TB. In our 
study we found the same tendency but it was not signif-
icant2.
In this study TB incidence rate seemed to be higher 
among males than females. Our findings affirm the find-
ings of  the First National Tuberculosis Prevalence Survey 
in Tanzania where prevalence was higher in males than  in 
females13. The findings are consistent with results from 
China14 and India15 as well as studies in Ethiopia and Bra-
zil where males were reported to have an increased risk 
of  TB even in HIV-infected population16,17. The lower 
incidence among females may be due to real lower in-
cidence but also to concealment of  a disease status by 
females because of  fear of  losing social status, marital 
problems, or harmful community reactions18.
Our study found that patients with active TB seemed to 
have lower CD4 cell count than those without TB. Similar 
findings were reported from Iran and Ethiopia19,20.
Our study had a high proportion (55%) of  patients who 
had only one visit and could not be found anymore. Pa-
tients may choose to be followed-up in a district where 
they do not live due to fear of  stigma. Another reason 
might be that persons never attend follow-up visits be-
cause of  the perception that HIV infected individuals 
would be visibly sick and they are not21. Lastly patients 
may have died and this was not recorded in CTC records.
Criteria for initiating ART in HIV-infected adults have 
changed since 2012. Tanzanian National AIDS Control 
Program recommends initiating ART in patients who (a) 
have current TB as AIDS defining illness or (b) CD4 be-
low 500 cells/mm3 or (c) WHO clinical stage 3 or 4.
The strength of  our study is that it was conducted using 
data that are routinely collected in Care and Treatment 
Centers and extra effort was done to trace those reported 
as loss to follow-up. Using regular surveillance data im-
plied some missing data. The limitation of  our study in-
cluded: a slightly biased sample size towards participants 
with complete data, which is a lower risk group with re-
spect to gender (females), WHO clinical stage (those with 
early stage disease i.e. stage 1&2), and those without prior 
TB history who might be have had relapse of  previous 
episode. Furthermore, numbers of  TB cases are small 
that might be due to use of   Ziehl Neelsen stain  to di-
agnose TB at the time of  the study, the incidence might 
have been higher if  culture or advanced TB diagnostics 
such as Xpert MTB/RIF had been used22.
Conclusion
The TB incidence among HIV-infected adults in Bagam-
oyo is much higher than the country’s estimated TB inci-
dence of  327 per 100,000 population23.Those with previ-
ous TB have a higher risk to contract TB again and need 
special attention. Although this study may have limited 
power, in combination with similar studies in other sites, 
a meta-analysis can help to get enough power to find sig-
nificant risk factors.
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